ELI-002
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ELI-002, covering 2025-01-17 to 2025-01-17. Get the full timeline:
Most recent: Clinical Trial Update: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors [Phase 1]